BGT 226 is a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin (PI3K/mTOR ) dual inhibitor which has shown to be effective with gefitinib in epidermal growth factor receptor (EGFR) inhibitor-sensitive non-small cell lung cancer (NSCLC) therapy. Molecular Formula: C32H29F3N6O6 Molecular Weight: 650.6 Storage and Stability: Store at -20C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Molekulargewicht:
650.6
CAS Nummer:
[1245537-68-1]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
